Valuation: ARS Pharmaceuticals, Inc.

Market Cap 783M 685M 631M 584M 1.11B 74.69B 1.13B 7.56B 2.96B 36.68B 2.94B 2.87B 127B P/E 2026 *
-4.43x
P/E 2027 * -8.19x
Enterprise Value 783M 685M 631M 584M 1.11B 74.69B 1.13B 7.56B 2.96B 36.68B 2.94B 2.87B 127B EV / Sales 2026 *
5.6x
EV / Sales 2027 * 3.18x
Free-Float
83.79%
Yield 2026 *
-
Yield 2027 * -
1 day-2.72%
1 week-7.94%
Current month-1.62%
1 month-16.26%
3 months-4.72%
6 months-39.66%
Current year-32.36%
1 week 7.49
Extreme 7.49
8.66
1 month 7.49
Extreme 7.49
10.87
Current year 7.03
Extreme 7.03
13.15
1 year 6.66
Extreme 6.66
18.63
3 years 2.55
Extreme 2.55
18.9
5 years 2.55
Extreme 2.55
18.9
10 years 2.55
Extreme 2.55
18.9
Manager TitleAgeSince
Chief Executive Officer 53 07/07/2026
Chief Tech/Sci/R&D Officer - 05/08/2015
Chief Tech/Sci/R&D Officer 57 01/09/2018
Director TitleAgeSince
Chairman 56 08/11/2022
Director/Board Member 55 01/08/2021
Director/Board Member 56 01/07/2017
Date Insider Type Main position Quantity % Market Cap.
07-01Free

Chief Executive Officer

898,456 0.9048%
06-24Free

Director

30,000 0.0302%
06-24Free

Director

30,000 0.0302%
Change 5-day change 1-year change 3-year change Capi.($)
-2.72%-7.94%-55.98%+28.55% 783M
+1.13%+2.51%+3.37%+11.35% 50.44B
+0.72%+1.00%+396.18%+624.25% 40.63B
+2.54%+0.93%+28.98%-3.62% 34.88B
+0.31%+1.74%+18.44%+59.76% 33.67B
-2.09%-1.98%+3.21%+33.56% 26.29B
-0.63%+0.34% - - 17.11B
+0.66%-3.96%+66.85%+127.36% 15.29B
-23.90%-21.43%+50.06%+53.83% 10.62B
+1.22%+0.40%+14.88%+22.30% 13.74B
Average -2.28%-3.23%+58.44%+106.37% 24.35B
Weighted average by Cap. -0.45%-0.63%+87.03%+139.41%

Financials

2026 *2027 *
Net sales 140M 122M 113M 104M 198M 13.35B 201M 1.35B 530M 6.55B 525M 514M 22.7B 246M 215M 198M 183M 348M 23.46B 354M 2.37B 931M 11.52B 923M 903M 39.9B
Net income -178M -155M -143M -133M -252M -16.96B -256M -1.72B -673M -8.33B -667M -653M -28.85B -97.73M -85.49M -78.84M -72.94M -138M -9.33B -141M -944M -370M -4.58B -367M -359M -15.87B
Net Debt - -
Logo ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.
Employees
157
Date Price Change Volume
09/07/26 $7.880 -2.72% 1,155,796
08/07/26 $8.100 -1.10% 2,036,599
07/07/26 $8.190 -1.68% 1,235,305
06/07/26 $8.330 -2.69% 1,124,311
02/07/26 $8.560 +7.81% 1,796,362
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
7.880USD
Average target price
26.75USD
Spread / Average Target
+239.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRY Stock